These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24131330)

  • 1. Determining carbapenemase activity with 18O labeling and targeted mass spectrometry.
    Wang M; Shen Y; Turko IV; Nelson DC; Li S
    Anal Chem; 2013 Nov; 85(22):11014-9. PubMed ID: 24131330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to detect carbapenemase production in Enterobacteriaceae by a rapid meropenem degradation assay.
    Foschi C; Franza V; Conti M; Tamburini MV; Roncarati G; Cordovana M; Smirnova V; Patrono D; Mancini R; Landini MP; Ambretti S
    New Microbiol; 2015 Oct; 38(4):571-6. PubMed ID: 26485016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenemases: molecular diversity and clinical consequences.
    Poirel L; Pitout JD; Nordmann P
    Future Microbiol; 2007 Oct; 2(5):501-12. PubMed ID: 17927473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
    Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbapenems in the USA: focus on doripenem.
    Lister PD
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Available carbapenems: Properties and differences].
    Martínez MJ; García MI; Sánchez EG; Sánchez JE
    Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():53-64. PubMed ID: 21130931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Flow Cytometry Test for Identification of Different Carbapenemases in Enterobacteriaceae.
    Silva AP; Faria-Ramos I; Ricardo E; Miranda IM; Espinar MJ; Costa-de-Oliveira S; Cantón R; Rodrigues AG; Pina-Vaz C
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3824-6. PubMed ID: 27021318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
    Stock I
    Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Carbapenemase-Producing Organisms with a Carbapenem-Based Fluorogenic Probe.
    Mao W; Xia L; Xie H
    Angew Chem Int Ed Engl; 2017 Apr; 56(16):4468-4472. PubMed ID: 28332754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance.
    Jeon JH; Lee JH; Lee JJ; Park KS; Karim AM; Lee CR; Jeong BC; Lee SH
    Int J Mol Sci; 2015 Apr; 16(5):9654-92. PubMed ID: 25938965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decoding the Structural Basis For Carbapenem Hydrolysis By Class A β-lactamases: Fishing For A Pharmacophore.
    Tondi D; Cross S; Venturelli A; Costi MP; Cruciani G; Spyrakis F
    Curr Drug Targets; 2016; 17(9):983-1005. PubMed ID: 26424401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Status report on carbapenemases: challenges and prospects.
    Patel G; Bonomo RA
    Expert Rev Anti Infect Ther; 2011 May; 9(5):555-70. PubMed ID: 21609267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in antibiotic resistance? Focus on beta-lactamases.
    Babic M; Hujer AM; Bonomo RA
    Drug Resist Updat; 2006 Jun; 9(3):142-56. PubMed ID: 16899402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence and phenotypic detection of class A carbapenemases among Escherichia coli and Klebsiella pneumoniae blood isolates at a tertiary care center.
    Gupta V; Bansal N; Singla N; Chander J
    J Microbiol Immunol Infect; 2013 Apr; 46(2):104-8. PubMed ID: 22541536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OXA-type carbapenemases.
    Walther-Rasmussen J; Høiby N
    J Antimicrob Chemother; 2006 Mar; 57(3):373-83. PubMed ID: 16446375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class A carbapenemases.
    Walther-Rasmussen J; Høiby N
    J Antimicrob Chemother; 2007 Sep; 60(3):470-82. PubMed ID: 17595289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QM/MM Simulations Reveal the Determinants of Carbapenemase Activity in Class A β-Lactamases.
    Chudyk EI; Beer M; Limb MAL; Jones CA; Spencer J; van der Kamp MW; Mulholland AJ
    ACS Infect Dis; 2022 Aug; 8(8):1521-1532. PubMed ID: 35877936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-hydrolyzing oxacillinase in high resistant strains of Acinetobacter baumannii isolated from India.
    Tiwari V; Kapil A; Moganty RR
    Microb Pathog; 2012 Aug; 53(2):81-6. PubMed ID: 22610043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.